LumiThera announces a distribution agreement for Valeda Light Delivery System with Miloftalmica in Italy

Wednesday, December 12, 2018

LumiThera Inc., a medical device company operating in the commercial phase focused on the development of photobiomodulation (PBM) therapies to treat eye disorders and diseases, has announced a distribution agreement with Miloftalmica to exclusively distribute the Valeda ™ Light Delivery System light application system for the treatment of the dry form of age-related macular degeneration (AMD) in Italy. Miloftalmica leads the Italian ophthalmology market since 1983 with an emphasis on the pursuit of innovation and excellence.

"Our new and exciting partnership with LumiThera is fully consistent with Miloftalmica's growth strategy and objectives, combining innovation and technology excellence." LumiThera's revolutionary light application system adds value to Miloftalmica's product portfolio. , said Andrea Pagani , CEO of Miloftalmica. "LumiThera truly allows us to offer the first approved treatment for those who suffer from the dry form of AMD, the leading cause of blindness in adults worldwide."

"The distribution agreement with Miloftalmica enables LumiThera to expand its commercialization in Europe and establishes a collaboration with a partner that offers imaging and diagnostic technologies complementary to our treatment for the dry form of DMAE," said Dr. Clark Tedford, president and CEO of LumiThera. "Miloftalmica is a leader in providing innovative technologies to ophthalmologists and we are excited to work with them to facilitate our treatment for the dry form of AMD."

The Valeda ™ Light Delivery System consists of a series of treatments based on light on the retinal cells, which generate an improved energy production and treat the inflammation, ischemia and metabolic dysfunction that contribute to the development of the disease.

Visit the company's website at  http://www.lumithera.com .

About LumiThera Inc.
LumiThera is a medical device company that operates in the commercial phase and whose goal is to treat people affected by eye disorders and diseases, including the dry form of age-related macular degeneration (AMD), one of The main causes of blindness in adults over 65 years. The company is a leader in the use of photobiomodulation to treat acute and chronic eye disorders and diseases, and is developing the Valeda ™ Light Delivery System light delivery system in clinics so that ophthalmologists can use it as medical treatment.

The device has been authorized by a notified body of the EU to use the CE marking, required for commercial use only in the European Union. Valeda ™ has not received approval from the Food and Drug Administration (FDA) for use in the US. UU

About Miloftalmica
Miloftalmica is a leading distributor of ophthalmic diagnostic technology in Italy, representing the leading brands of superior quality and with an excellent performance capacity. Since its foundation in 1983, Miloftalmica has been dedicated to achieving the full satisfaction of its customers. The company renews its mission every day by constantly improving its services, actively researching those products that best adapt to the needs of its clients and establishing exclusive and long-term international partnerships: Heidelberg Engineering, Imagine Eyes, Maculogix, Quantel Medical and Forus Health.

For more information about Miloftalmica, visit  http://www.miloftalmica.it